In this new CMTRF-funded study the clinical candidate, called ARM-101, will deliver the miRNA inside a viral carrier called an adeno-associated virus (AAV). In animal-based studies, ARM-101 will be delivered by a single injection adjacent to the spinal cord, in a standard clinical manner that is used to deliver many other drugs including painkillers. The goals of this study include understanding if and how ARM-101 is reaching the Schwann cells and having the desired effect; learning more about the drug’s dynamics while in the body, dosage versus outcome; and ultimately, achieving clinically meaningful functional improvements.